Adaptimmune Therapeutics Utdelning 2024

Vad gör Adaptimmune Therapeutics?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics är ett av de mest populära företagen på Eulerpool.com.